Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases

被引:478
作者
Sun, L [1 ]
Tran, N [1 ]
Tang, F [1 ]
App, H [1 ]
Hirth, P [1 ]
McMahon, G [1 ]
Tang, C [1 ]
机构
[1] SUGEN Inc, Redwood City, CA 94063 USA
关键词
D O I
10.1021/jm980123i
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs). These compounds have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells. By modifying the 3-substituted indolin-2-ones, we have identified compounds which showed selective inhibition of the ligand-dependent autophosphorylation of various RTKs at submicromolar levels in cells. Structure-activity analysis for these compounds and their relative potency and selectivity to inhibit particular RTKs has determined that (1) 3-[(five-membered heteroaryl ling)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK activity, (2) 3-(substituted benzylidenyl)indolin-2-ones containing bulky group(s) in the phenyl ring at the C-3 position of indolin-2-ones showed high selectivity toward the EGF and Her-2 RTKs, and (3) the compound containing an extended side chain at the C-3 position of the indolin-2-one (16) exhibited high potency and selectivity when tested against the PDGF and VEGF (Flk-1) RTKs. Recent published crystallographic data for two of these 3-substituted indolin-2-ones provides a rationale to suggest that these compounds may bind in the ATP binding pocket of RTKs. The structure-activity analysis supports the use of subsets of these compounds as specific chemical leads for the development of RTK-specific drugs with broad application for the treatment of human diseases.
引用
收藏
页码:2588 / 2603
页数:16
相关论文
共 19 条
[1]   OXIDATION AND CLAISEN CONDENSATION PRODUCTS OF 3-NITRO-O-XYLENE [J].
ASKAM, V ;
DEEKS, RHL .
JOURNAL OF THE CHEMICAL SOCIETY C-ORGANIC, 1969, (14) :1935-&
[2]   THE MOLECULAR-GENETICS OF CANCER [J].
BISHOP, JM .
SCIENCE, 1987, 235 (4786) :305-311
[3]   Tyrosine kinase inhibitors .8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor [J].
Bridges, AJ ;
Zhou, H ;
Cody, DR ;
Rewcastle, GW ;
McMichael, A ;
Showalter, HDH ;
Fry, DW ;
Kraker, AJ ;
Denny, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (01) :267-276
[4]   A NEW EFFICIENT AND MILD SYNTHESIS OF 2-OXINDOLES BY ONE-POT WOLFF-KISHNER LIKE REDUCTION OF ISATIN DERIVATIVES [J].
CRESTINI, C ;
SALADINO, R .
SYNTHETIC COMMUNICATIONS, 1994, 24 (20) :2835-2841
[5]  
FRY D, 1996, ANNU REP MED CHEM, P51
[6]   GROWTH-FACTORS AND TYROSINE PROTEIN-KINASES IN NORMAL AND MALIGNANT MELANOCYTES [J].
HALABAN, R .
CANCER AND METASTASIS REVIEWS, 1991, 10 (02) :129-140
[7]  
Klohs Wayne D., 1997, Current Opinion in Oncology, V9, P562, DOI 10.1097/00001622-199711000-00012
[8]   Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors [J].
Mohammadi, M ;
McMahon, G ;
Sun, L ;
Tang, C ;
Hirth, P ;
Yeh, BK ;
Hubbard, SR ;
Schlessinger, J .
SCIENCE, 1997, 276 (5314) :955-960
[9]   Tyrosine kinase inhibitors .11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: Synthesis, biological evaluation, and modeling of the mode of binding [J].
Palmer, BD ;
TrumppKallmeyer, S ;
Fry, DW ;
Nelson, JM ;
Showalter, HDH ;
Denny, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (10) :1519-1529
[10]  
PLOWMAN GD, 1994, DRUG NEWS PERSPECT, V7, P334